Those numbers and press everyone. at the level to financial to available during and time more today. you good review last we much I'm detail to results going the that and release night. filed details night's Joe, this in all the also in morning, are last call Thanks, XX-Q not summary take your Form in
I like the in and XX, that ended XX-month completed the in June sales comparison we X- top demonstrate that line since June to XXXX. capacity work expansion we we would point same investing during periods had X-, largely XX, strong results have periods growth XXXX. very XXXX, out been have the production to that These ended
was $XX.X the matched This of target. ended with the XX% success approximately During period X-month 'XX, annual million level approximately adequate has line. not to million line $XX.X top million. output estimated would This June annualize bottom of capacity goods production to margin full approximately finished XX, $XX gross our been or
sales the of the this ended X-month a but as target. of margin from period XX% still to well June XX, XXXX, XX% X-month product period is percentage short June XXXX, our during gross Our ended improve did XX% during XX,
higher began some contamination from to level, events 'XX incurred we at XXXX. product significant operate late this early to As output we
thoroughly. events these investigated have We
our which to cows caused for problems raw anticipated were as sourced an is meet our in unusually material, demand. of farms more contracted Some rapidly by bioburden source more we with colostrum, high
been problem largely ongoing it this believe We that front-end now monitoring require forward. has going fixed, will while
all to and within of USDA-approved that the of some the processes remediation adequately were several believe our events adjustments, outline contamination at output. The also higher level was equipment the run contamination of production. of required optimized We not caused production that by
the is and is August also We X. gross that we data sales to XX-Q of at production prior the scrap cost in periods filing we margin, disclosed in it's sales inventory but not is lower have as our when key of it filing detail backlog million the scrap the of remediate the XX-Q slowed the our the just miss set which yet reduced This $X.X orders, contaminations. disclosed was reason also cleared not our in in
implemented most be very present. April to without recent of steps and response because appear to since have XXXX to events, the New in contamination far we contamination then during successful remediation run the so
For USDA clarity, product to these testing sold throughout that release I'd passed to had confirm contamination was like that events, all market requirements. final
Like components. we inflationary everything buy. the economy, just are about challenging pressures companies facing and cost of in we This most this on other impacts labor
In gross is during margin deterioration incurred that this production have addition, the period. the of cause we other the yield losses
that targets the some improve yields to specific process on We have we are in working disclosed quarters. coming
I look quality in hard. We over high source very is something for is the growth XX that same back, After We When that running control at being process a sudden bioburden with milk. years, work better needed understandable. now this source material, I growth. farm of to see successfully the
in equipment our processing and we our process We pushed similar have incurred were harder. now, as well-established that done challenges
natural is also more introduce heat heat reduce antibodies. bioburden, this A but contamination reaction to to to kills
while to We $XXX,XXX But to We bioburden with effectively we at depreciation To more production ended have X-month forward. the maintain of XXXX. be allowing output also to negative credit to and June and In run have until be on successful, equipment significant levels interest, $X million June being. expenditure are during possible, investments cash XXXX, believe our XXXX. expense time capital ended the EBITDA XX, that frozen we avoid period that line implemented where EBITDA that level no million to us improve negative yields. and nonessential period optimizing going we XX, to our the we we are able the earnings available response, sales, were amortization doubt, of outstanding us must maximizing acceptable draw X-month prudent tight. No for and $X.X from during taxes, mix is controls September operational continue is those the before strong improvements operate good future or yields.
With breakdowns events contamination with higher
big summary Further, data. regards the the financial to discussion release our other [ and provides results Form press results, analysis. XX-Q the financial unaudited sheet that's P&L provides unaudited balance details picture.
With So all management's and audited the and some the ]
As I review time take mentioned, to detail. on this call that all your I'll now in
CMC CMC commercial our Re-Tain. section In our we complete the will on First as what of have section remain with letter FDA bring the as to for focused we May, steps in opportunity issued the see and response final Defense We technical to third the of in work Re-Tain regulatory through process we submission the to a technical market. effort
our some which is submission, incomplete subject a about minor to force letter, to Pursuant submission the requiring has the FDA X-month typically review. a provided questions
items FDA are has the potentially through complex. However, review a the handled resubmission could indicated that because period not be this shortened open
Most however, that until the inspectional FDA drug observations our critical product of section is at required line, time to also we that manufacturer the technical CMC are has facilities not resolved. contract the the resubmit
Our contract responses observations July. its submitted manufacturer to in the inspectional early
facts market forward. we unique with to circumstances, obtain our This are are manufacturer and the FDA we process, contract of to drug working move continuing the Regardless, an the and product Given and review. and is part expedited excited with site an discard mass the to or we dairy treated remain withhold subclinical today's FDA-required without in is restrictions. poised antibiotics to way meat milk traditional label a that novel alternative revolutionize
and on a our our click to our believe Investors update of it night, as and our as strategy results. presentation website posted financial very good An August see just I to slide Corporate copy. review Lastly, I corporate was website section us of last for summary business you provides or well contact objectives current encourage our a the Presentation deck.
be will take happy I to questions. that, With your
operator Let's up the have lines. the open
